Hamilton Lane enters August with its most interesting setup in months — a 14% weekly rally powered by earnings-day buying, while the insiders who loaded up at lower prices look increasingly well-timed.
The insider story is the standout. Executive Co-Chairman Hartley Rogers spent over $8 million buying shares across late May and June 11, when the stock traded in the high $70s to low $90s. A director added $1.1 million on the same June 11 date, and the COO put in a smaller buy alongside them. Across the trailing 90 days, net insider buying totals roughly $15.2 million — a concentrated cluster at prices well below the current $101.61 close. That kind of coordinated buying from senior management, in size, at lower prices, is worth noting now that the stock has caught up.
The bigger near-term signal may be in options rather than short positioning. Put-to-call ratio has dropped sharply to 0.74, well below its 20-day average of 1.04, and a full reversal from the defensive posture that dominated June and early July — when PCR ran above 1.5 and briefly hit 2.1. That prior hedging has unwound fast. The shift suggests investors who were protecting against downside into earnings have now closed those positions, leaving options positioning notably more bullish-leaning than the recent average. The borrow market adds little intrigue here: availability is loose at 577%, and cost to borrow is just 0.54% — a 27% week-on-week uptick from a very low base, more noise than signal. Short interest at 9.6% of free float is real but has been drifting lower for a month, down about 9% over 30 days, and the lending environment offers no squeeze catalyst.
The Street is recalibrating after the print. Both Oppenheimer and Keefe, Bruyette & Woods raised price targets on August 5 — the same day as the result — with Oppenheimer moving to $182 and KBW to $116. That spread reflects genuine disagreement about valuation. Morgan Stanley sits at the cautious end with an Equal-Weight and a $123 target set on July 21. The mean target across analysts is $130, implying roughly 28% upside from current levels — but that figure is dragged upward by Oppenheimer's outlier $182. Goldman holds a Buy with a $128 target from late June. The bull case centres on the evergreen platform: FPAUM up 65% year-on-year to $12.5 billion, with strong forward fee projections. Bears flag a modest sequential dip in capital raised and limited product transparency. The stock's PE has expanded about 1.1 turns over the past month to nearly 12.9x, reflecting the price move, while EV/EBITDA has compressed slightly — the re-rating is real but not yet stretched on earnings multiples.
Peers moved strongly on the week too, though Hamilton Lane still led the group. OWL gained nearly 18%, TPG added 12%, and ARES rose nearly 12% — confirming the broader alternative asset manager sector caught a bid, not just HLNE specifically. BX and KKR lagged, up 2.5% and 5.4% respectively. Hamilton Lane's 14% weekly gain sits comfortably above the sector median, consistent with the post-earnings reaction. The stock also reported a +6.1% single-day move after its May 21 print, so the pattern of positive earnings reactions is not new.
The next earnings date is September 10. Between now and then, the key question is whether short sellers — who have been trimming positions into this rally — continue to reduce, or whether the rapid recovery from June lows prompts fresh conviction on either side.
See the live data behind this article on ORTEX.
Open HLNE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
